Alchemia Limited – Product Pipeline Review – Q1 2011
Global Market Direct’s pharmaceuticals report, “Alchemia Limited - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
- Alchemia Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Alchemia Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Alchemia Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Alchemia Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Alchemia Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Alchemia Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Alchemia Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill
Alchemia Limited – Product Pipeline Review – Q1 2011 Reference Code: GMDHC0689CDB Publication Date: MAR 2011 Alchemia Limited – Product Pipeline Review – Q1 2011 GMDHC0689CDB / Published MAR 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Alchemia Limited – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 5 List of Figures 5 Alchemia Limited Snapshot 6 Alchemia Limited Overview 6 Key Information 6 Key Facts 6 Alchemia Limited – Research and Development Overview 7 Key Therapeutic Areas 7 Alchemia Limited – Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products – Monotherapy 11 Alchemia Limited – Pipeline Products Glance 12 Alchemia Limited – Late Stage Pipeline 12 Phase III Products/Combination Treatment Modalities 12 Alchemia Limited Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Alchemia Limited–Early Stage Pipeline Products 14 Pre-Clinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Alchemia Limited – Drug Profiles 16 HA-Irinotecan 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 HyDox 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 HyFIVE 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Antibiotic Programme 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 HyACT-Avastin 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 HyACT-Erbitux 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 HyACT-Gemzar 22 Alchemia Limited – Product Pipeline Review – Q1 2011 GMDHC0689CDB / Published MAR 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2) Alchemia Limited – Product Pipeline Review Product Description 22 Mechanism of Action 22 R&D Progress 22 HyACT-Navelbine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 HyACT-Paraplatin 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Opioid Programme 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Somatostatin Programme 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 VAST Based Drug For Pain 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Alchemia Limited – Pipeline Analysis 28 Alchemia Limited – Pipeline Products by Therapeutic Class 28 Alchemia Limited - Pipeline Products By Target 29 Alchemia Limited – Pipeline Products by Route of Administration 31 Alchemia Limited – Pipeline Products by Molecule Type 32 Alchemia Limited – Recent Pipeline Updates 33 Alchemia Limited - Discontinued Pipeline Products 34 Discontinued Pipeline Product Profiles 34 ACL16907 34 VAST Based Drug For Obesity 34 Alchemia Limited – Company Statement 35 Alchemia Limited – Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Recent Developments 38 Jul 14, 2010: Alchemia And Dr Reddy's Expand Fondaparinux Marketing Collaboration 38 Jul 12, 2010: Alchemia’s Phase III Cancer Trial Adopted By National Institute Of Health Research Clinical Research Network 38 Mar 19, 2010: Emisphere And Alchemia Partner To Develop Oral Formulation Of Fondaparinux 39 Mar 14, 2006: Alchemia, Meditech Research Limited To Merge 40 Mar 14, 2006: Alchemia, Meditech Research Limited To Merge 40 Jun 07, 2002: Meditech Announces Positive HyDOX Results 41 Financial Deals Landscape 43 Alchemia Limited, Deals Volume Summary, 2004 to YTD 2011 43 Alchemia Limited, Deals Summary By Region, 2004 to YTD 2011 44 Alchemia Limited, Deals Summary, 2004 to YTD 2011 45 Alchemia Limited – Product Pipeline Review – Q1 2011 GMDHC0689CDB / Published MAR 2011 ©Global Markets Direct.. This report is a licensed product and is not to be ph
Pages to are hidden for
"Alchemia Limited – Product Pipeline Review – Q1 2011"Please download to view full document